Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDR132L in Patients With Reduced LVEF After Myocardial Infarction
NCT05350969Phase 2Completed
- Sponsor
- Cardior Pharmaceuticals
- Start
- Jul 2022
- Primary completion
- Sep 2024
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 8
01
Overview
A Phase 2 trial of CDR132L in heart failure (HF), myocardial infarction (MI), sponsored by Cardior Pharmaceuticals. Started Jul 2022; status: completed.
02
Drugs
CDR132L
03
Conditions
heart failure (HF)myocardial infarction (MI)
Beyond the preview
Go deeper on NCT05350969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05350969.